Salarius Pharmaceuticals attempts to regain Nasdaq compliance with reverse stock split


Houston-based Salarius Pharmaceuticals announced a 1-for-25 reverse stock split as the company looks to regain compliance with the Nasdaq.

Previous One of St. Louis region's largest foundations names new CEO as it shifts focus
Next Owners of Sale Pepe help revamp Pacific’o on the Beach